Anti-Human PD-L1/B7-H1 Reference Antibody (Avelumab, RUO)
- Catalog number: BS11469
- Availability: In Stock
$176.00
- Ex Tax: $176.00
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Human
Isotype: IgG1-lambda
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1.64mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: B7-H1,Programmedcelldeath1ligand1,PDCD1ligand1,PDCD1L1,B7homolog1,PDCD1LG1,PDL1,hPD-L1,Programmeddeathligand1,B7H1,PD-L1,CD274
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: MSB-0010718C,MSB0010682,CAS:1537032-82-8
Background: Programmed cell death 1 ligand 1 (CD274/PD-L1) is a ~33 kDa protein. Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10). Can also act as a transcription coactivator: in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis. CD274 is the therapeutic target of atezolizumab (Tecentriq) and durvalumab (Imfinzi).
References:
1. Freeman, GJ. et al. (2000) The Journal of experimental medicine 192, 1027-34. PMID: 11015443
2. Mezzadra, R. et al. (2017) Nature 549, 106-110. PMID: 28813410
3. Burr, ML. et al. (2017) Nature 549, 101-105. PMID: 28813417
4. Huang, X. et al. (2019) Cancer immunology research 7, 1580-1590. PMID: 31399419
5. Kennedy, A. et al. (2023) The EMBO journal 42, e111556. PMID: 36727298
6. Dong, H. et al. (1999) Nature medicine 5, 1365-9. PMID: 10581077
7. Hou, J. et al. (2020) Nature cell biology 22, 1264-1275. PMID: 32929201
Note: For research use only. Not suitable for clinical or therapeutic use.
Images
-
BioactivityDetects CD274/PD-L1/B7-H1 in indirect ELISAs.
-
SDS-PAGESDS-PAGE for Research Grade Avelumab.
-
Flow CytometryFlow-cytometry using anti-human CD274 antibody. Untransfected cells (blue Histogram) and Transfected cells (Yellow Histogram) were stained with an anti-human CD274 monoclonal antibody (Catalog HV974036) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a Goat Anti-Human IgG H&L Polyclonal Antibody, FITC (abinScience: HF690414) and cells analysed on a NovoCyte Flow Cytometer.
-
Flow CytoMetryFlow-cytometry using FITC anti-human CD274 antibody. MDA-MB-231 cells were stained with an irrelevant antibody (Blue Histogram) or an FITC anti-human CD274 monoclonal antibody (Catalog: HV974036, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, cells analysed on a NovoCyte Flow Cytometer.
-
Flow CytoMetryFlow-cytometry using APC anti-human CD274 antibody. MDA-MB-231 cells were stained with an irrelevant antibody (Blue Histogram) or an APC anti-human CD274 monoclonal antibody (Catalog: HV974036, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, cells analysed on a NovoCyte Flow Cytometer.
